Esther Schuler

Heinrich Heine University Düsseldorf

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Guido Kobbe

Heinrich Heine University Düsseldorf

Rainer Haas

Heinrich Heine University Düsseldorf

Ulrich Germing

Heinrich Heine University Düsseldorf

Thomas Schroeder

Düsseldorf University Hospital

Christina Rautenberg

Essen University Hospital

Norbert Gattermann

Heinrich Heine University Düsseldorf

Ulrich Germing

Heinrich Heine University Düsseldorf

Barbara Hildebrandt

Heinrich Heine University Düsseldorf

Jennifer Kaivers

University of Duisburg-Essen

Gesine Bug

Frankfurt Cancer Institute

Cooperative Institutions

Heinrich Heine University Düsseldorf

Heidelberg University

Düsseldorf University Hospital

University Hospital Heidelberg

German Cancer Research Center

Charité - Universitätsmedizin Berlin

Freie Universität Berlin

Humboldt-Universität zu Berlin

University of Freiburg

University Medical Centre Mannheim

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Improving the accuracy of prognostication in chronic myelomonocytic leukemia

Expert Review of Anticancer Therapy (2020)

Jennifer Kaivers Esther Schuler Barbara Hildebrandt Beate Betz Christina Rautenberg

Chronic myelomonocytic leukemia (CMML) is a hematological malignancy that is extremely variable regarding its clinical course. It may present either as a chronic disorder with mild symptoms and low disease burden for several years, thereby justifying a watch-and-wait-strategy, or may soon progress to acute myeloid leukemia (AML) leaving allogeneic stem cell transplantation as the only curative treatment option.Attempts have been made to integrate clinical, cytogenetic, and molecular parameters into scoring systems aiming at providing reliable prognostic information. In this article, we discuss several prognostic parameters and validate prognostic scores in a cohort of 645 patients with CMML.We show that the CPSS (CMML prognostic scoring system) is a useful prognostic tool. The integration of molecular data into the new CPSS-mol will further improve prognostic accuracy, primarily by identifying an increased proportion of higher-risk patients.

Chronic myelomonocytic leukemia

Hematologic malignancy

Expert opinion

10.1080/14737140.2020.1796644

Cite

Citations (4)

Modulation of histamine-induced bronchoconstriction with inhaled, oral, and intravenous clemastine in normal and asthmatic subjects.

Thorax (1981)

V. Hartmann H Magnussen J Holle Esther Schuler

Although histamine plays an important role in the pathophysiology of asthma through stimulation of H1 receptors, H1 antagonists are of only limited use in this disease when given orally. In order to investigate the pharmacological response to a specific H1 antagonist administered by different routes, we measured the effect of inhaled clemastine on airway responsiveness to histamine aerosol and compared the results with those after oral and intravenous administration in normal and asthmatic subjects. Inhalation of 0.6 mg clemastine provided significant protection without side effects and was comparable to intravenous administration of 1.0 mg in both groups. In normal subjects 2.0 mg clemastine orally was significantly less effective than the two other routes of administration whereas in asthmatics an enhanced reaction to histamine was observed.

Histamine H1 Antagonists

10.1136/thx.36.10.737

Cite

Citations (9)

Long-term outcome of high risk patients with myelodysplastic syndromes or secondary acute myeloid leukemia receiving intensive chemotherapy

Annals of Hematology (2018)

Esther Schuler Natalie Zadrozny Sabine Blum Thomas Schroeder Corinna Strupp

Hematology

10.1007/s00277-018-3466-7

Cite

Citations (12)

Genome-wide DNA methylation analysis pre- and post-lenalidomide treatment in patients with myelodysplastic syndrome with isolated deletion (5q)

Annals of Hematology (2021)

Anna Hecht Julia A. Meyer Johann-Christoph Jann Katja Sockel Aristoteles Giagounidis

Abstract Myelodysplastic syndrome (MDS) with isolated deletion of chromosome 5q (MDS del5q) is a distinct subtype of MDS with quite favorable prognosis and excellent response to treatment with lenalidomide. Still, a relevant percentage of patients do not respond to lenalidomide and even experience progression to acute myeloid leukemia (AML). In this study, we aimed to investigate whether global DNA methylation patterns could predict response to lenalidomide. Genome-wide DNA methylation analysis using Illumina 450k methylation arrays was performed on n =51 patients with MDS del5q who were uniformly treated with lenalidomide in a prospective multicenter trial of the German MDS study group. To study potential direct effects of lenalidomide on DNA methylation, 17 paired samples pre- and post-treatment were analyzed. Our results revealed no relevant effect of lenalidomide on methylation status. Furthermore, methylation patterns prior to therapy could not predict lenalidomide response. However, methylation clustering identified a group of patients with a trend towards inferior overall survival. These patients showed hypermethylation of several interesting target genes, including genes of relevant signaling pathways, potentially indicating the evaluation of novel therapeutic targets.

Hematology

10.1007/s00277-021-04492-1

Cite

Citations (1)

Validation of a New Clinically Based Classification System for Stratification of Prognosis in Patients with CMML

Leukemia Research (2017)

Christina Rautenberg Esther Schuler Kathrin Nachtkamp T J Schroeder Sabine Blum

Risk Stratification

Stratification (seeds)

10.1016/s0145-2126(17)30372-7

Cite

Citations (2)

Survey of Treatment of 1021 Patients with Myelodysplastic Syndromes in a Tertiary Referal Center 2007-2013

Blood (2014)

Jennifer Schemenau Kathrin Nachtkamp Blanca Xicoy Andrea Kuendgen Corinna Strupp

10.1182/blood.v124.21.4647.4647

Cite

Citations (0)

Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation with Venetoclax, Hypomethylating Agents and DLI - a Retrospective Multi Center Study

Blood (2019)

Esther Schuler Eva‐Maria Wagner‐Drouet Salem Ajib Gesine Bug Martina Crysandt

Venetoclax

Decitabine

Azacitidine

Hypomethylating agent

Salvage therapy

10.1182/blood-2019-125087

Cite

Citations (3)

Opportunities and Limitations of Pelvic Exenteration Surgery

Cancers (2021)

Björn Lampe Verónica Luengas-Würzinger Jürgen Weitz Stephan Roth Friederike Rawert

The practice of exenterative surgery is sometimes controversial and has garnered a certain scepticism. Surgical studies are difficult to conduct due to insufficient data. The aim of this review is to present the current standing of pelvic exenteration from a surgical, gynaecological and urological point of view.

Pelvic exenteration

10.3390/cancers13246162

Cite

Citations (17)

Quantitative Next-Generation Sequencing (NGS) Based Monitoring of Minimal Residual Disease (MRD) Predicts Imminent Relapse in Patients with Myeloid Malignancies after Allogeneic Hematopoietic Stem Cell Transplantation

Blood (2017)

Christina Rautenberg Beate Betz Dagmar Wieczorek Barbara Hildebrandt Kathrin Nachtkamp

CEBPA

Minimal Residual Disease

10.1182/blood.v130.suppl_1.2005.2005

Cite

Citations (1)